Top

Published in:

01-07-2009

Overexpression and Interactions of Interleukin-10, Transforming Growth Factor β, and Vascular Endothelial Growth Factor in Esophageal Squamous Cell Carcinoma

Authors: Mehran Gholamin, Omeed Moaven, Bahram Memar, Moein Farshchian, Hossein Naseh, Reza Malekzadeh, Masoud Sotoudeh, Mohammad Taghi Rajabi-Mashhadi, Mohammad Naser Forghani, Farid Farrokhi, Mohammad Reza Abbaszadegan

Published in: World Journal of Surgery | Issue 7/2009

Abstract

Background

Sharing the role of immune suppression, interleukin-10 (IL-10), transforming growth factor β (TGF-β), and vascular endothelial growth factor (VEGF) are critical genes in several aspects of tumorigenesis. To elucidate the role of these cytokines in esophageal squamous cell carcinoma (ESCC), their relative mRNA expression in tumoral tissue compared with corresponding tumor-free tissue was evaluated.

Methods

A total of 49 patients with histologically confirmed ESCC were included in the study prior to any therapeutic interventions. Quantitative analysis of the mRNA expression was performed by real-time reverse transcription-polymerase chain reaction and the clinicopathologic associations were assessed.

Results

The mRNA of IL-10, VEGF, and TGF-β was frequently overexpressed in 53.2%, 44.9%, and 37.5% of ESCC patients, respectively. TGF-β was significantly co-expressed with IL-10 and with VEGF. Although VEGF was not independently associated with increased tumor size (p = 0.065), concomitant overexpression of VEGF with TGF-β was significantly correlated with increased size of the tumor (p < 0.05).

Conclusions

Overexpression of IL-10, TGF-β, and VEGF plays an important role in ESCC and consequently leads to the frequent event of immune evasion in ESCC. TGF-β is concomitantly overexpressed with IL-10 and with VEGF in ESCC. A stimulatory signal from TGF-β to VEGF is necessary for VEGF to promote tumor progression.

Sadjadi A, Nouraie M, Mohagheghi MA et al (2005) Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev 6:359–363PubMed

Yang L, Parkin DM, Li L et al (2003) Time trends in cancer mortality in China: 1987–1999. Int J Cancer 106:771–783PubMedCrossRef

Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25:581–611PubMedCrossRef

Bates DO, Curry FE (1996) Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. Am J Physiol 271:H2520–H2528PubMed

Ellis LM, Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 8:579–591PubMedCrossRef

Huang CL, Liu D, Ishikawa S et al (2008) Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur J Cancer 44:2680–2688PubMedCrossRef

Furlan D, Sahnane N, Carnevali I et al (2008) Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. Hum Pathol 39:1483–1494PubMedCrossRef

Oh SY, Kwon HC, Kim SH et al (2008) Clinicopathologic significance of HIF-1alpha, p53, and VEGF expression and preoperative serum VEGF level in gastric cancer. BMC Cancer 8:123

Chen XY, Li JS, Liang QP et al (2008) Expression of PC cell-derived growth factor and vascular endothelial growth factor in esophageal squamous cell carcinoma and their clinicopathologic significance. Chin Med J (Engl) 121:881–886

10.

Moses HL, Yang EY, Pietenpol JA (1990) TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63:245–247PubMedCrossRef

11.

Massague J (1990) The transforming growth factor-beta family. Annu Rev Cell Biol 6:597–641PubMedCrossRef

12.

Roberts AB, Sporn MB, Assoian RK et al (1986) Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167–4171PubMedCrossRef

13.

Fontana A, Constam DB, Frei K et al (1992) Modulation of the immune response by transforming growth factor beta. Int Arch Allergy Immunol 99:1–7PubMedCrossRef

14.

Luwor RB, Kaye AH, Zhu JH (2008) Transforming growth factor-beta (TGF-β) and brain tumours. J Clin Neurosci 15:845–855PubMedCrossRef

15.

Fukai Y, Fukuchi M, Masuda N et al (2003) Reduced expression of transforming growth factor-beta receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J Cancer 104:161–166PubMedCrossRef

16.

Villanueva A, Garcia C, Paules AB et al (1998) Disruption of the antiproliferative TGF-β signaling pathways in human pancreatic cancer cells. Oncogene 17:1969–1978PubMedCrossRef

17.

Grady WM, Myeroff LL, Swinler SE et al (1999) Mutational inactivation of transforming growth factor β receptor type II in microsatellite stable colon cancers. Cancer Res 59:320–324PubMed

18.

Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor (beta) in human disease. N Engl J Med 343:228

19.

Volk H, Asadullah K, Gallagher G et al (2001) IL-10 and its homologs: important immune mediators and emerging immunotherapeutic targets. Trends Immunol 22:414–417PubMedCrossRef

20.

Wakkach A, Cottrez F, Groux H (2000) Can interleukin-10 be used as a true immunoregulatory cytokine? Eur Cytokine Netw 11:153–160PubMed

21.

Kurte M, López M, Aguirre A et al (2004) A synthetic peptide homologous to functional domain of human IL-10 down-regulates expression of MHC class I and transporter associated with antigen processing 1/2 in human melanoma cells. J Immunol 173:1731–1737PubMed

22.

Kundu N, Dorsey R, Jackson MJ et al (1998) Interleukin-10 gene transfer inhibits murine mammary tumors and elevates nitric oxide. Int J Cancer 76:713–719PubMedCrossRef

23.

Kohno T, Mizukami H, Suzuki M et al (2003) Interleukin-10-mediated inhibition of angiogenesis and tumor growth in mice bearing VEGF-producing ovarian cancer. Cancer Res 63:5091–5094PubMed

24.

Asadullah K, Sterry W, Volk HD (2003) Interleukin-10 therapy: review of a new approach. Pharmacol Rev 55:241–269PubMedCrossRef

25.

Koliopanos A, Friess H, di Mola FF et al (2002) Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg 26:420–427PubMedCrossRef

26.

Oka M, Hirose K, Iizuka N et al (1995) Cytokine mRNA expression patterns in human esophageal cancer cell lines. J Interferon Cytokine Res 15:1005–1009PubMedCrossRef

27.

Loges S, Clausen H, Reichelt U et al (2007) Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis. Clin Cancer Res 13:76–80PubMedCrossRef

28.

Kapral M, Strzalka B, Kowalczyk M et al (2008) Transforming growth factor beta isoforms (TGF-beta1, TGF-beta2, TGF-beta3) messenger RNA expression in laryngeal cancer. Am J Otolaryngol 29:233–237PubMedCrossRef

29.

Diaz-Chavez J, Hernandez-Pando R, Lambert PF et al (2008) Down-regulation of transforming growth factor-beta type II receptor (TGF-betaRII) protein and mRNA expression in cervical cancer. Mol Cancer 7:3PubMedCrossRef

30.

Abe H, Yamanishi T, Mashidori T et al (2008) Significant association of interleukin 10 receptor mRNA levels with renal cell carcinoma metastasis. Biomed Res 29:19–25PubMedCrossRef

31.

Ohm JE, Gabrilovich DI, Sempowski GD et al (2003) VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood 101:4878–4886PubMedCrossRef

32.

Yang WF, Yu JM, Zuo WS et al (2006) Expression of CD80, CD86, TGF-beta1 and IL-10 mRNA in the esophageal carcinoma. Zhonghua Zhong Liu Za Zhi 28:762–765PubMed

33.

Kaklamani VG, Pasche B (2004) Role of TGF-beta in cancer and the potential for therapy and prevention. Expert Rev Anticancer Ther 4:649–661PubMedCrossRef

34.

Loskog A, Dzojic H, Vikman S et al (2004) Adenovirus CD40 ligand gene therapy counteracts immune escape mechanisms in the tumor microenvironment. J Immunol 172:7200–7205PubMed

35.

Nagata J, Kijima H, Hatanaka H et al (2002) Correlation between interleukin 10 and vascular endothelial growth factor expression in human esophageal cancer. Int J Mol Med 10:169–172PubMed

36.

Merogi AJ, Marrogi AJ, Ramesh R et al (1997) Tumor–host interaction: analysis of cytokines, growth factors, and tumor-infiltrating lymphocytes in ovarian carcinomas. Hum Pathol 28:321–331PubMedCrossRef

37.

D’Orazio TJ, Niederkorn JY (1998) A novel role for TGF-beta and IL-10 in the induction of immune privilege. J Immunol 160:2089–2098PubMed

38.

Li D, Zhang C, Song F et al (2009) VEGF regulates FGF-2 and TGF-beta1 expression in injury endothelial cells and mediates smooth muscle cells proliferation and migration. Microvasc Res 77:134–142PubMedCrossRef

39.

Wang XJ, Dong Z, Zhong XH et al (2008) Transforming growth factor-beta1 enhanced vascular endothelial growth factor synthesis in mesenchymal stem cells. Biochem Biophys Res Commun 365:548–554PubMedCrossRef

40.

Boström K, Zebboudj AF, Yao Y et al (2004) Matrix GLA protein stimulates VEGF expression through increased transforming growth factor-beta1 activity in endothelial cells. J Biol Chem 279:52904–52913PubMedCrossRef

41.

Benckert C, Jonas S, Cramer T et al (2003) Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 63:1083–1092PubMed

42.

Ferrari G, Pintucci G, Seghezzi G et al (2006) VEGF, a prosurvival factor, acts in concert with TGF-beta1 to induce endothelial cell apoptosis. Proc Natl Acad Sci USA 103:17260–17265PubMedCrossRef

Title: Overexpression and Interactions of Interleukin-10, Transforming Growth Factor β, and Vascular Endothelial Growth Factor in Esophageal Squamous Cell Carcinoma
Authors: Mehran Gholamin
Omeed Moaven
Bahram Memar
Moein Farshchian
Hossein Naseh
Reza Malekzadeh
Masoud Sotoudeh
Mohammad Taghi Rajabi-Mashhadi
Mohammad Naser Forghani
Farid Farrokhi
Mohammad Reza Abbaszadegan
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: World Journal of Surgery / Issue 7/2009
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI: https://doi.org/10.1007/s00268-009-0070-y

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Overexpression and Interactions of Interleukin-10, Transforming Growth Factor β, and Vascular Endothelial Growth Factor in Esophageal Squamous Cell Carcinoma

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2009

Preventing Parastomal Herniation: Is Prophylactic Prosthetic Mesh Absolutely Necessary?

Benefits Versus Risks: A Prospective Audit

Feasibility of Intraoperative Neuromonitoring During Thyroid Surgery After Administration of Nondepolarizing Neuromuscular Blocking Agents

Clinicopathological Features of Tumors as Predictors of the Efficacy of Primary Neoadjuvant Chemotherapy for Operable Breast Cancer: Reply to Letter

Limitations of “Classic” Risk Factors to Predict Neoadjuvant Chemotherapy Response for Operable Breast Cancer

Risk Factors for Abdominal Wound Dehiscence in Children: A Case-Control Study